MedTrace Logo

Investigating the Clinical Consequences of Flutemetamol-PET-scanning

NCT02353949 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2020-01-21

No results posted yet for this study

Summary

The study examines subjects where there might be an indication for Amyloid-PET according to the Criteria defined by the Amyloid Imaging Task Force. In these subjects the impact of a Flutemetamol (Vizamyl)-Positron-Emission-Tomography -Scan (PET) on clinical management and disease course will be studied over 6 months.

Conditions

Interventions

DRUG

Flutemetamol (Vizamyl)

PET-MR Scan using the radiotracer Flutemetamol (Vizamyl) for diagnostic purpose

Sponsors & Collaborators

  • ETH Zurich

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Christoph Hock, MD, Prof. · University of Zurich, Institute for Regenerative Medicine, Center for Prevention and Dementia Therapy

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2019-12-10
Completion
2019-12-10

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02353949 on ClinicalTrials.gov